Fort L.P. trimmed its holdings in Hill-Rom Holdings, Inc. (NYSE:HRC) by 13.9% in the 1st quarter, according to its most recent disclosure with the SEC. The firm owned 20,829 shares of the medical technology company’s stock after selling 3,357 shares during the period. Fort L.P.’s holdings in Hill-Rom were worth $2,095,000 at the end of the most recent quarter.
Other institutional investors have also modified their holdings of the company. Signaturefd LLC grew its position in Hill-Rom by 53.3% in the first quarter. Signaturefd LLC now owns 302 shares of the medical technology company’s stock worth $30,000 after acquiring an additional 105 shares during the period. Lloyd Advisory Services LLC. purchased a new position in Hill-Rom in the fourth quarter worth approximately $41,000. CWM Advisors LLC purchased a new position in Hill-Rom in the first quarter worth approximately $39,000. Total Clarity Wealth Management Inc. purchased a new position in Hill-Rom in the fourth quarter worth approximately $53,000. Finally, Optimum Investment Advisors purchased a new position in Hill-Rom in the first quarter worth approximately $50,000. Institutional investors own 85.68% of the company’s stock.
NYSE:HRC traded down $3.89 during midday trading on Thursday, reaching $95.55. The company had a trading volume of 11,267 shares, compared to its average volume of 663,742. The firm has a market capitalization of $6.98 billion, a price-to-earnings ratio of 45.61, a PEG ratio of 1.23 and a beta of 0.70. The stock’s fifty day simple moving average is $104.24 and its 200-day simple moving average is $105.66. Hill-Rom Holdings, Inc. has a 12-month low of $72.29 and a 12-month high of $117.50. The company has a current ratio of 1.52, a quick ratio of 1.22 and a debt-to-equity ratio of 1.20.
Hill-Rom (NYSE:HRC) last released its earnings results on Friday, May 1st. The medical technology company reported $1.28 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.15 by $0.13. The firm had revenue of $723.20 million during the quarter, compared to analyst estimates of $701.72 million. Hill-Rom had a return on equity of 22.60% and a net margin of 5.04%. Hill-Rom’s revenue was up 1.3% compared to the same quarter last year. During the same period last year, the business posted $1.14 earnings per share. As a group, sell-side analysts expect that Hill-Rom Holdings, Inc. will post 5.47 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Friday, June 19th will be paid a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a yield of 0.92%. The ex-dividend date of this dividend is Thursday, June 18th. Hill-Rom’s dividend payout ratio is presently 17.32%.
In other Hill-Rom news, SVP Paul Sherwood Johnson sold 10,344 shares of the firm’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $103.95, for a total value of $1,075,258.80. Following the sale, the senior vice president now directly owns 4,999 shares in the company, valued at $519,646.05. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Amy M. Dodrill sold 3,189 shares of the firm’s stock in a transaction on Tuesday, April 7th. The shares were sold at an average price of $110.00, for a total value of $350,790.00. Following the completion of the sale, the insider now owns 1,389 shares in the company, valued at $152,790. The disclosure for this sale can be found here. 0.65% of the stock is owned by company insiders.
Several research analysts have recently commented on the company. UBS Group lowered their price target on Hill-Rom from $130.00 to $125.00 and set a “buy” rating for the company in a research report on Monday, May 4th. Morgan Stanley lowered their price target on Hill-Rom from $138.00 to $125.00 and set an “overweight” rating for the company in a research report on Friday, March 27th. Finally, Barclays restated a “buy” rating and set a $125.00 price target on shares of Hill-Rom in a research report on Tuesday, April 14th. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $126.20.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Featured Article: Percentage Decliners
Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings, Inc. (NYSE:HRC).
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.